Articles On Biotron (ASX:BIT)

Australian company Biotron (ASX:BIT) has announced that all participants in the Phase 2 COVID-19 clinical trial of its antiviral drug BIT225 have completed dosing, marking the end of the clinical phase of the study.

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Lumos surges on patent granted in Japan and Europe  Singular Health announces strategic investment in the US LGP’s founder steps down from CEO role   Lumos surges after patent granted in Europe and Japan Lumos Diagnostics (ASX:LDX) surged...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Sydney-based company Inventia Life Science has announced a new distribution agreement with Biotron Healthcare.

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Biotron (BIT) enters phase II of its COVID-19 clinical trial using its lead antiviral drug, BIT225, to test 60 male and female patients between 18-59 years old The trial will determine if BIT225 reduces the SARS-CoV-2 virus load in the b...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX 200 edges higher,  small cap index falls 0.44% 7 out of 11 sectors were in the green with Tech up 1.25% Downbeat RBA Governor speech highlights all the things that could go wrong with the economy   Last night the leads were decent, th...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Biotron (BIT) completes recruitment of the phase two HIV-1 clinical trial with its lead antiviral drug, BIT225The study will be carried out in people infected with HIV-1 who have achieved partial immune reconstitution despite treatmentParti...

Biotron (ASX:BIT) has announced the commencement of a human clinical trial of its lead antiviral drug BIT225 against COVID-19.

The ASX 200 falls 2.6%  after Wall St rout  Small caps recover manfully to be just 1% lower  AQC is turning out be a hell of a ride   Firstly, the Benchmark ASX 200 is down about 2.5% on Wednesday. It’s a fair whack, but hardly worse tha...

Biotron commences human trial of COVID-19 Pancreatic trial news from Noxopharm and Clarity Pharma Vectus completes dosing of last cohort   Biotron (ASX:BIT) jumped 6% this morning after announcing the start of a human trial of its lead an...

Biotron (BIT) launches a human trial of its lead antiviral drug against COVID-19The trial of Biotron’s BIT225 compound has been approved as a sub-study of an ongoing phase two HIV-1 clinical trial, which is currently in progress in Thailand...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Biotron (ASX:BIT) has announced that a Phase 2 HIV-1 clinical trial of its lead antiviral drug, BIT225, is fully recruited.

The ASX 200 loses 1.2%, XEC sheds 0.9% Weak leads, sour sentiment hobble Asia-Pac markets BPH adds 200% on word ex-PM shot down its prospects   The S&P/ASX Emerging Companies (XEC) index has lost 0.9% on Tuesday, the benchmark ASX 200...

Biotron (BIT) finishes recruiting patients for its phase two HIV-1 clinical trial of its lead antiviral drug BIT225 The clinical trial is being conducted in Thailand and aims to determine the safety and efficacy of BIT225 on a daily basis...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Biotron (BIT) receives positive US FDA guidance for its lead antiviral drug, BIT225, as a potential treatment of COVID-19 The guidance follows the company sending a briefing package for a proposed phase two clinical trial Managing Director...

Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w...

The interest rate rise came and the markets fell, then turned a corner. The question now is — will the wheels stay on? Already lagging, the ASX Emerging Companies (XEC) index has closed 0.8% lower. The benchmark has closed 0.4% behind. The...

Biotron (ASX:BIT) has announced its lead clinical drug BIT225 has demonstrated effective protection from severe disease in mice with established SARS-CoV-2 infection in a new animal study performed at The SCRIPPS Research Institute...

Central Banks have their fingers on the fun button this week, and the markets are pricing in the big push. The Emerging Companies Index (XEC) has been sunk on day dot, down 2.3%. The S&P/ASX 200 index was down 1.2% at 4.15pm, with this...

Those that believe that COVID-19 is yesterday’s news should look at the Biotron Limited (ASX: BIT) share price today. Shares in the small cap biotech jumped 37.5% to 9.9 cents each after reporting positive COVID-19 animal trial results tod...

Biotech company Biotron (BIT) says a new study of its lead clinical drug, BIT225, has been shown to be effective against established SARS-CoV-2 in mice The study showed BIT225 to protect against severe disease in mice that were infected wi...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Biotron (ASX:BIT) says its lead clinical asset BIT225 has again demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal studies performed at The SCRIPPS Research Institute in the US....

The Emerging Companies Index (XEC) climbed more than 2% higher on Thursday, before closing at 1.9%, while its benchmark colleague – the upmarket ASX 200 followed Wall Street’s ascendence, trading up a shade over 1% after the Fed lifted inte...

Biotron’s (BIT) lead drug, BIT225, has again demonstrated its effectiveness against SARS-CoV-2 (COVID-19) in animals The success of the second study was indicated by the significant prevention of body weight loss and no death reported in S...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

While US markets rose after the Fed outlined plans to gradually withdraw stimulus, our markets did not follow suit even amidst a sea of deals. Leading the charge today was IGO (ASX:IGO) which after months of negotiations looks to have inked...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

For the second month in a row the ASX was hit by a major sell-off in the last few days of the month and it took the bourse from what was then a 0.5% gain to a 1.56% loss in November. Just when we thought we were out of the worst of COVID, w...

ASX recovered some lost ground in arvo trade but still finished 0.54% down, as markets continue to be shaken by the discovery of the omicron variant of COVID-19 and falling oil prices. Resources and tech managed to finish in the green – by...